Clinical Trials Logo

HIV Infection Primary clinical trials

View clinical trials related to HIV Infection Primary.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05947266 Recruiting - Clinical trials for HIV Infection Primary

Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a culturally tailored engagement and retention intervention for Haitian Immigrants Living With HIV (HILWH). The main questions it aims to answer are: - Does this intervention result in measurable engagement and retention in care? - Does this intervention result in measurable viral suppression within 6 months? Participants will - participate in a pilot health intervention entailing 4 individual meetings, approximately once monthly over a six-month period and completing research questionnaires at enrollment, post-intervention and at 6 months post-enrollment. - Six participants who have completed the pilot intervention and agree to take part, will participate in the photovoice portion of the study. This activity will consist of 6 additional meetings where participants will be taught about using photographs to illustrate their experience participating in the study and take and display photographs.

NCT ID: NCT05780073 Recruiting - Clinical trials for HIV Infection Primary

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

Start date: October 16, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatinib in People with Human Immunodeficiency Virus (PWH) on suppressive Combined Antiretroviral Therapy (cART),. The main question it aims to answer are: - How safe and tolerable is Dasatinib administered at low dose - To evaluate the on-target/biological effect of Dasatinib in "in vitro" T-cells activation and its durability after completion of the treatment - To evaluate the effect of Dasatinib on inflammation and immune activation, on the HIV-1 reservoir, and on cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) cell counts. - To characterize Dasatinib concentrations in plasma and its relationships with the observed effects. Participants will be treated with Dasatinib or matched Placebo once a day for 24 weeks. Suppressive cART will remain unchanged during the entire study. Participants will be followed until week 48, in a total of eleven visits.

NCT ID: NCT04663152 Recruiting - Clinical trials for HIV Infection Primary

Integrated Navigation Services for Treatment Adherence, Counseling, and Research

INSTACARE
Start date: July 26, 2023
Phase: N/A
Study type: Interventional

The goal of this research is to determine whether a Community Health Worker (CHW) intervention including a mobile telehealth (M-Health) component can help achieve long term viral suppression among Black people with poorly controlled HIV.